Shanu Modi
沙努·莫迪
MD
Medical Oncologist肿瘤内科医师
👥Biography 个人简介
Shanu Modi at Memorial Sloan Kettering Cancer Center led the DESTINY-Breast04 trial that established trastuzumab deruxtecan as a breakthrough treatment for HER2-low breast cancer, expanding treatment options for a large patient population previously ineligible for HER2-targeted therapy. She is a leading voice in the HER2-low breast cancer paradigm.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
HER2-Low Breast Cancer Treatment
Led DESTINY-Breast04 establishing T-DXd as the first effective HER2-targeted therapy for HER2-low breast cancer, redefining a new patient population eligible for HER2-directed treatment.
ADC Clinical Development
Contributed to the clinical development of multiple antibody-drug conjugates in breast cancer, defining dosing, toxicity profiles, and patient selection criteria.
Representative Works 代表性著作
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
NEJM (2022)
DESTINY-Breast04 trial establishing T-DXd in HER2-low breast cancer.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
NEJM (2020)
DESTINY-Breast01 pivotal trial.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 沙努·莫迪 的研究动态
Follow Shanu Modi's research updates
留下邮箱，当我们发布与 Shanu Modi（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment